The impact of xanthine oxidase (XO) on hemolytic diseases

Heidi M. Schmidt¹², Eric E. Kelley³, Adam C. Straub¹²⁵

¹ Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, United States
² Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, United States
³ Department of Physiology and Pharmacology, West Virginia University, School of Medicine, Morgantown, WV, United States

ARTICLE INFO

Keywords:
Hemolysis
Heme toxicity
Xanthine oxidase
Reactive oxygen species
Therapeutics

ABSTRACT

Hemolytic diseases are associated with elevated levels of circulating free heme that can mediate endothelial dysfunction directly via redox reactions with biomolecules or indirectly by upregulating enzymatic sources of reactive species. A key enzymatic source of these reactive species is the purine catabolizing enzyme, xanthine oxidase (XO) as the oxidation of hypoxanthine to xanthine and subsequent oxidation of xanthine to uric acid generates superoxide (O₂⁻) and hydrogen peroxide (H₂O₂). While XO has been studied for over 120 years, much remains unknown regarding specific mechanistic roles for this enzyme in pathologic processes. This gap in knowledge stems from several interrelated issues including: 1) lethality of global XO deletion and the absence of tissue-specific XO knockout models have coalesced to relegate proof-of-principle experimentation to pharmacology; 2) XO is mobile and thus when upregulated locally can be secreted into the circulation and impact distal vascular beds by high-affinity association to the glycosylated on the endothelium; and 3) endothelial-bound XO is significantly resistant (> 50%) to inhibition by allopurinol, the principle compound used for XO inhibition in the clinic as well as the laboratory. While it is known that circulating XO is elevated in hemolytic diseases including sickle cell, malaria and sepsis, little is understood regarding its role in these pathologies. As such, the aim of this review is to define our current understanding regarding the effect of hemolysis (free heme) on circulating XO levels as well as the subsequent impact of XO-derived oxidants in hemolytic disease processes.

1. Introduction

Excess circulating free heme is associated with numerous hemolytic diseases including sickle cell disease (SCD), thalassemia, sepsis, cardiac bypass, and malaria [1-5]. Oxidation of reduced heme (Fe²⁺ → Fe³⁺) can result in heme and hemoglobin (Hb) release from red blood cells (RBCs) into the circulation [2,6]. Under normal physiologic conditions, Hb is bound by haptoglobin (Hp) and targeted to macrophages where the complex is taken up via endocytosis and degraded [2]. Likewise, free heme in the plasma is either bound by hemopexin (Hx) or immediately degraded to iron, carbon monoxide and biliverdin by the enzyme heme oxygenase-1 (HO-1) [1]. Hx targets heme primarily to the liver and spleen, allowing heme to be cleared through the endothelium, endocytosed by hepatocytes and degraded by cellular HO-1 or redistributed for heme iron recycling [Fig. 1] [2,6]. However, under conditions of severe hemolysis, Hx and HO-1 become saturated, resulting in oxidative damage to surrounding tissues due to a decrease in heme degradation and simultaneous increase in circulating free heme [2]. For example, reaction of free heme with O₂ can generate superoxide (O₂⁻), and subsequently elevate hydrogen peroxide (H₂O₂) levels via spontaneous or enzymatic dismutation as well as hydroxyl radical (HO•) levels by reaction of peroxide(s) with transition metals including heme-iron (Fe). Enhanced abundance of these reactive species mediate lipid, protein, and DNA oxidation resulting in cell and tissue damage, endothelial dysfunction, and loss of vascular homeostasis [Fig. 1] [1,7]. While the catalytically-active Fe in heme as well as “free Fe” derived from heme is considered the seminal source of oxidants in hemolytic disease, subsequent contributions from
alternative sources are significant to the progression of this inflammatory process. For example, free heme activates toll-like receptor 4 (TLR4) signaling, resulting in activation of pro-inflammatory pathways which include amplification of ROS levels from sources alternative to those generated via Fe-mediated reactions (Fig. 1) [2,8].

In addition to hemolysis, reactive oxygen species (ROS) and reactive nitrogen species (RNS) (e.g. nitric oxide (NO), nitrogen dioxide (NO2) and peroxynitrite (ONOO−)) are generated under numerous pathological conditions that often accompany hemolytic diseases (e.g. ischemia-reperfusion injury and chronic inflammation) [9–11]. The main pathways in which O2− is generated include the mitochondrial electron transport chain, nicotinamide-adenine dinucleotide phosphate (NADPH) oxidases, uncoupled nitric oxide synthase (NOS), and xanthine oxidase (XO) [10]. XO is one such mechanism that is noted to be upregulated in hemolytic disease [12]. XO generates oxidants by shuttling electrons derived from purine oxidation to either univalently (O2−) or divalently (H2O2) reduce O2 [12]. Della Corte and Stirpe made several important discoveries in the late 1960s and early 1970s showing that XOR is irreversibly or reversibly converted to XO via proteolysis or oxidation of cysteine residues, respectively[19–21]. As the crystal structure of bovine milk XDH was solved, the site of proteolysis was identified as following Lys551 and the sites of oxidation were identified as Cys535 and Cys592 with formation of a disulfide bridge [18].

2. Xanthine oxidase

Xanthine oxidoreductase (XOR) is a name commonly used to encompass two interconvertible forms of the same enzyme: dehydrogenase (XDH) and oxidase (XO) [16]. XOR is transcribed and translated as XDH, a ∼300 kDa homodimer consisting of four redox centers in each subunit: one molybdenum cofactor (Mo-co), one flavin adenine dinucleotide (FAD) site, and two Fe2S2 sites [17]. XDH catalyzes the oxidation of hypoxanthine to xanthine and xanthine to uric acid at the Mo-co site and electrons are shuttled via the two Fe2S2 clusters to the FAD site where NAD+ is reduced to NADH. XOR exists primarily as XDH intracellularly; yet, once in the extracellular space and circulation XO is the dominant isoform [17]. The principle difference between XO and XDH is their oxidizing substrate affinity where XO demonstrates diminished affinity for NAD+ and over 11-fold increased affinity for O2 [18]. As such, electrons derived from hypoxanthine and xanthine oxidation by XO are quickly accepted by O2 to generate O2− and H2O2 [12]. Della Corte and Stirpe made several important discoveries in the late 1960s and early 1970s showing that XOR is irreversibly or reversibly converted to XO via proteolysis or oxidation of cysteine residues, respectively[19–21]. As the crystal structure of bovine milk XDH was solved, the site of proteolysis was identified as following Lys551 and the sites of oxidation were identified as Cys535 and Cys592 with formation of a disulfide bridge [18].
3. XOR regulation

While much is known regarding XOR biochemistry, transcriptional and translational regulation is much less understood. The human \( xdh \) gene is located on the p22 band of chromosome two and contains several possible binding sites for translational modification: four CCAAT/enhancer binding sites, three IL-6 responsive elements, an NF-kB site, and TNFα, interferon-γ, and interleukin-1 responsive units [22]. XOR expression is reported to be controlled by a variety of factors including hormones, growth factors, and inflammatory cytokines; yet, the most studied effector of XOR expression/activity is hypoxia [23,24]. While many studies have described transcriptional and post-translational up-regulation of XOR by severe hypoxia [25–28], modest hypoxia (10% \( O_2 \)) is also capable of inducing significant elevation of XOR expression, activity, export from endothelial cells, and XO-dependent ROS production [24]. The described moderate hypoxic conditions are comparable to levels observed in congestive heart failure patients [24]. Parks and Granger were the first to describe an elevation in purine catabolites under hypoxic conditions as they attributed the increased hypoxanthine observed during hypoxia to the breakdown of ATP → ADP → AMP → adenosine → inosine → hypoxanthine (purine degradation pathway) [29]. This is crucial in terms of XO function as increased levels of hypoxanthine require increased XO activity for further oxidation to uric acid, all while generating \( O_2^- \) and \( H_2O_2 \) as byproducts [29]. It is important to note that elevated circulating free heme can induce RBC lysis resulting in release of ATP into the circulation [30–32]. This ATP is quickly catabolized to adenosine then to hypoxanthine creating a milieu similar to that described above for moderate hypoxia [30]. Elevated levels of hypoxanthine may consequently trigger upregulation of XOR activity in addition to activating purine salvage via hypoxanthine-guanine phosphoribosyltransferase (HPRGT) [33]. Interestingly, we have previously described upregulation of XOR via adenosine activation of adenosine \( A_2B \) receptors on endothelial cells [24]. Therefore, the combination of increased adenosine and hypoxanthine levels could significantly amplify XOR activity and allied ROS generation during hemolytic crisis; a process already wrought with abundant oxidant generation attributable to heme itself.

4. XOR-endothelial interaction

A critical concept when considering the impact of XOR on disease processes in general and hemolytic disease specifically, is that XOR is mobile and has a high affinity (\( K_D = 6 \text{ nM} \)) for glycosaminoglycans (GAGs) on the apical surface of the vascular endothelium [34,35]. As such, XOR can be upregulated in one anatomic site (e.g., liver), exported to the circulation, bound to endothelial GAGs and thus sequestered in vascular beds distal from the site of origin [34–38]. When coupled to the elevated circulating levels of hypoxanthine, it is in this setting that XO can critically contribute to oxidant-mediated vascular dysfunction [39]. Binding and immobilization of XOR on the vascular GAGs also has significant kinetic consequences including alteration in the relative amounts of \( O_2^- \) and \( \text{H}_2\text{O}_2 \) produced as well as resistance to inhibition by pyrazolopyrimidine-based inhibitors (see Therapeutic Inhibitors of XO, below) [40–42]. In the aggregate, mobility and capacity to avidly associate to the endothelium in a manner that is resistant to inhibition affords XO the ability to critically contribute to loss of vascular homeostasis.

5. Therapeutic inhibitors of XO

There are currently two XO inhibitors that are FDA approved for the treatment of gout: allopurinol and febuxostat [43]. While allopurinol has been in the clinic for over fifty years, febuxostat (Uloric®) was approved in 2009 [43]. Current reports suggest allopurinol may be the superior drug for diminishing uric acid levels to the extent that symptoms of gout are alleviated; however, febuxostat is a more potent XO inhibitor and may be more useful in treating diseases with elevated XO activity at the surface of endothelial cells [43]. Allopurinol is a hypoxanthine mimetic that prevents oxidation of hypoxanthine and xanthine at the Mo-co site of XOR [44]. XOR oxidizes allopurinol, a suicide inhibitor, with the transfer of two electrons to form oxypurinol, the pharmacologically active form of the drug, which then competitively inhibits XO [40,45]. Since the oxidation of allopurinol to oxypurinol results in reduction of XOR, \( O_2^- \) and \( \text{H}_2\text{O}_2 \) are generated as unfortunate byproducts [40]. In addition, GAG-immobilized XOR is resistant to inhibition by allo/oxypurinol. For example, concentrations (200–400 \( \mu \text{M} \)) of allo/oxypurinol, greater than the clinical working range (20–80 \( \mu\text{M} \)) are required to achieve 45–50% inhibition of XO [41]. While allopurinol is effective at relieving symptoms of gout, it may be a poor choice for targeting endothelial-associated XO-derived ROS generation.

Febuxostat is reported to have a \( K_I \) some 6000 times lower than allopurinol and does not react directly with the Mo-co site of XOR, but rather binds the pocket leading to the active site via electrostatic interaction thus blocking purine access. As such, it does not induce enzyme turn-over and unwanted production of \( O_2^- \) and \( \text{H}_2\text{O}_2 \) [40,46,47]. This makes febuxostat an ideal pharmaceutical for pathologic conditions where \( O_2^- \) and \( \text{H}_2\text{O}_2 \) generated by XO contribute to endothelial injury. The IC\(_{50}\) of febuxostat (4.4 \( \mu\text{M} \)) did increase 2.5-fold when XO was bound by GAGs, but this is significantly lower than the 22-fold increase observed with allopurinol (64 \( \mu\text{M} \)) [40]. Febuxostat completely inhibited \( O_2^- \) formation at or below 50 \( \mu\text{M} \), a concentration well below the clinical \( C_{\text{max}} \) (15 \( \mu\text{M} \)) [40].

Whereas both pyrazolopyrimidine-based inhibitors and febuxostat are effective in reducing uric acid levels and oxidant generation by inhibiting XO, they are not without shortcomings. For example, clinical administration of allopurinol: 1) is limited to significantly reduced dosing in patients with preexisting renal disease, 2) is known to mediate substantive hypersensitivity issues which also limits dosage and 3) effects alternative purine catabolic pathways [15,48]. While febuxostat has demonstrated superior specificity and potency to allo/oxypurinol, it too has been associated with negative clinical outcomes. For example, febuxostat administration has been associated with rhabdomyolysis in patients with chronic kidney disease (CKD) [49] and has been shown to be non-inferior to allopurinol regarding rates of adverse cardiovascular events where all-cause mortality and cardiovascular mortality were greater in febuxostat-treated patients than patients treated with allopurinol [50]. When taken together, the issues related to currently available FDA-approved XO inhibition approaches may indeed limit the potential for their effective use in hemolytic disease, affirming the need for alternative approaches to alter XO activity.

6. XOR, ROS and hemolytic diseases

Upregulation of XDH has been associated with hypoxia-induced vaso-occlusive crisis in SCD mice and humans [12,51]. Aslan and colleagues demonstrated that ischemia/reperfusion injury in SCD mice resulted in release of XDH from the liver into the circulation, rapid conversion to XO via plasma proteases, immobilization on endothelial GAGs, and represented a major source of \( O_2^- \) and \( \text{H}_2\text{O}_2 \) in the vascular compartment [12], as depicted in Fig. 2. In this setting, XO-derived oxidants can alter cell signaling processes as well as induce overt damage [12]. For example, diminution in \(^{\text{NO}}\)-mediated signaling (e.g. vasodilatory response) can result from the diffusion-limited reaction between XO-derived \( O_2^- \) and \(^{\text{NO}}\) to form \(^{\text{NO}}=\text{NOO}^-\). In addition, both XO-derived \( O_2^- \) and \( \text{H}_2\text{O}_2 \) can mediate protein and lipid oxidation which can affect vascular homeostasis by also altering signaling pathways directly (e.g. oxidation of eNOS-associated BH₃) or indirectly via disruption of cellular membrane integrity. Evidence for the contribution of XO to oxidant load is also revealed by substantially elevated circulating XO in SCD patients compared to healthy controls [51].

Hepatic ischemic injury and hypoxia, in mice and rats, also increase XDH release from the liver into the vasculature and induce rapid
conversion of XDH to XO during reperfusion [52,53]. Due to the relatively high circulating half-life of XO, significant damage can be done to the endothelium due to XO-dependent oxidant generation [52]. Elevated XO levels were observed in diseases involving liver injury such as hepatitis, jaundice, and chronic renal failure (secondary effects on the liver) [52]. Of particular interest is that elevated levels of circulating XO are reported to positively associate with chronic liver disease (cirrhosis, chronic hepatitis and cholestatic disorders); yet, they do not correlate with indices of liver damage, suggesting a signaling event alternative to hepatocellular damage is present, and thus may drive upregulation of XDH with subsequent release into the circulation [54]. However, patients with virus-related cirrhosis demonstrated significantly enhanced levels of circulating XO that did positively correlate with the extent of liver damage as indicated by assessment of ALT leaving the field a bit unclear at present [55].

More specifically related to “hemolytic” disease are patients with malaria and/or sepsis. Asymptomatic malaria patients demonstrate a two-fold elevation in circulating XO levels compared to controls whereas patients hospitalized with severe malaria have plasma XO levels over 3.25-fold greater than asymptomatic individuals and thus 6.5-fold greater than controls [4]. Similarly, upon diagnosis, sepsis patients who did not subsequently survive present with significantly elevated plasma (2.2-fold) XO activity [5]. However, 24 h post diagnosis these non-survivors displayed less plasma XO activity than survivors; thus, indicating a temporal relationship regarding circulating XO activity and the severity of the disease as well as the overall outcome. Regardless of survival outcomes, plasma XO activity correlated positively with indices of oxidant stress including protein carbonylation and lipid peroxidation. This principle was also seen in a rodent model of experimental sepsis where treatment with allopurinol and/or metal chelation therapy with desferrioxamine significantly abrogated the abundance of biomolecular free radicals indicating critical contributions from both XO and Fenton-type reactions stemming from RBC lysis [56].

While it is clear that there are contributory roles for XO in hemolytic disease, it is equally clear that the mechanisms underpinning specific signaling events leading to upregulation of XDH, triggers to release XDH into the circulation and the subsequent impact of circulating XO remain to be defined. For example, it has been suggested that TLR-4 signaling serves to elevate XOR levels [57]; yet, there are no reports revealing empirical evidence that this is the case. On the other hand, it has been reported that XO-derived ROS were essential for TLR4-induced NFAT5 (nuclear factor of activated T cells) activation of murine macrophages; again, leaving the field a bit unclear [58]. This gap in our current understanding of the linkage between heme overload and upregulation of XDH affirms the need for further study.

Hx is a natural antioxidant that binds heme as it is released during hemolysis and targets the complex to the liver parenchymal cells for degradation and recycling of the Hx and iron [59]. However, increased nitrification of Hx during inflammation can diminish the protective antioxidant properties during heme toxicity [59]. Erythrocytes undergo a significant amount of oxidative stress and ROS production and thus require a number of enzymatic and non-enzymatic antioxidants including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), glutathione (GSH) and vitamins E and C [60]. SCD hemoglobin generates twice as much O2?, H2O2 and HO’ compared to normal hemoglobin, and thus have increased antioxidant function often resulting in antioxidant deficiencies [60]. Antioxidant therapeutic approaches are being examined as an option for treating SCD because they can be administered at low cost through food and can be administered in combination with hydroxyurea to decrease oxidative stress [61].

7. Summary and conclusions

The high levels of hemolysis associated with hemolytic diseases, cause a saturation of protective pathways resulting in an increase in O2?, H2O2 and HO’ generation and activation of inflammatory pathways [2,8]. XO is one mechanism of ROS generation that has been observed
in elevated circulating levels in murine models of hemolytic disease and clinically. Circulating XO can significantly contribute to the oxidant load in the vascular compartment by binding to the endothelial glycosylax [34,35]. In this setting XO is resistant to inhibition by clinically applicable concentrations of alloxypurinol and thus may serve to amplify the oxidant load derived from heme-related reactions and thus exacerbate an existing oxidant assault. However, the signaling events that link elevation in heme concentration and upregulation/export of cellular XDH are not defined. Further exploration of these signaling events will provide a clearer understanding of the role of XOR in hemolytic disease and likely improve clinical practices and outcomes.

Acknowledgements

Funds were provided by National Institutes of Health Grants R01 HL 133864 and R01 HL 128304 (ACS), P01 AG043376 and P20 GM109098 (EKK), American Heart Association (AHA) Grant-in-Aid 16GRNT27250146 (ACS) and Bayer Pharma Sponsored Research Grant (ACS). Additionally, other support was provided by the Institute for Transfusion Medicine and the Hemophilia Center of Western Pennsylvania (ACS). Graphical design was provided by Anita Impagliazzo.

Disclosure and conflicts of interest

The authors declare no conflicts of interest.

References

[1] F. Vinci, et al., Hemopexin therapy improves cardiovascular function by pre-venting heme-mediated endothelial toxicity in mouse models of hemolytic disease, Circulation 127 (12) (2013) 1317–1329.
[2] F. Vinci, et al., Hemopexin therapy reverts heme-induced proinflammatory pheno-type switching of macrophages in a mouse model of sickle cell disease, Blood 127 (4) (2016) 473–486.
[3] M.D. Jain, R. Cabrerizo-Sanchez, K. Karkouti, T. Yau, J.M. Pendergrast, C.M. Cserti-Jナ, J.D. Belcher, et al., Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: role of heme oxygenase-1 induction, PLoS One 13 (4) (2018) e0196455.
[4] E. Takimoto, D.A. Kass, Role of oxidative stress in cardiac hypertrophy and re-dox Signal. 6 (6) (2004) 967.
[5] C. Enroth, B.T. Eger, K. Okamoto, T. Nishino, T. Nishino, E.F. Pai, Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion, Proc. Natl. Acad. Sci. USA 97 (20) (2000) 10723–10728.
[6] E. Della Corte, F. Strupe, The regulation of rat-liver xanthine oxidase: activation by proteolytic enzymes, FEBS Lett. 2 (2) (1968) 83–84.
[7] F. Strupe, E. Della Corte, The regulation of rat liver xanthine oxidase. Conversion in vitro of the enzyme activity from dehydrogenase (type D) to oxidase (type O), J. Biol. Chem. 244 (14) (1969) 3855–3863.
[8] E.D. Corte, F. Strupe, The regulation of rat liver xanthine oxidase. Involvement of thiol groups in the conversion of the enzyme activity from dehydrogenase (type D) into oxidase (type O) and purification of the enzyme, Biochem. J. 126 (3) (1972) 739–745.
[9] J. Hewinson, C.R. Stevens, T.M. Millar, Vascular pathology and pathology of cir-culating xanthine oxidoreductase: from nucleotide sequence to functional enzyme, Redox Rep. 9 (2) (2004) 71–79.
[10] M.G. Battelli, L. Polito, M. Bortolotti, A. Bolognesi, Xanthine oxidoreductase-de-rived reactive species: physiological and pathological factors, Oxid. Med. Cell Longev. 2016 (2016) 352579.
[11] E.E. Kelley, et al., Moderate hypoxia induces xanthine oxidoreductase activity in arterial endothelial cells, Free Radic. Biol. Med. 40 (6) (2006) 952–959.
[12] W.B. Poss, T.P. Hückstedt, P.C. Panus, B.A. Freeman, J.R. Hoidal, Regulation of xanthine dehydrogenase and xanthine oxidase activity by hypoxia, Am. J. Physiol. 270 (6 pt 1) (1996).
[13] J. Linder, E. Martelin, R. Lapatto, K.O. R avio, Posttranslational inactivation of human xanthine oxidoreductase by oxygen under standard cell culture conditions, Am. J. Physiol. Cell Physiol. 285 (1) (2003) C48–C55.
[14] P.M. Hassoun, et al., Regulation of endothelial cell xanthine dehydrogenase xan-thine oxidase gene expression by oxygen tension, Am. J. Physiol. 266 (2 Pt 1) (1994) L163–L171.
[15] S. Durr, A. S. Bukholy, D. N. Granger, Role of oxygen-derived free radicals in di-sloidal tract diseases, Surgery 94 (3) (1983) 415–422.
[16] T. Nishino, K. Okamoto, B.T. Eger, T. Nishino, S. Kondo, E.F. Pai, An extremely small, E.M. Schmidt et al., Allopurinol: insights from studies of dose-response relationships, Expert Opin. Drug Saf. 9 (6) (2010) 661–667.
[17] I.R. López-Cruz, Plasma hypoxanthine-guanine phosphoribosyl transferase activity but then what do you do? Cold agglutinins in sickle cell disease; pathophysiology and potential implications for disease management, Am. J. Hematol. 86 (6) (2011) 484.
[18] Redox Signal. 6 (6) (2004) 1329.
[19] R.I. López-Cruz, Plasma hypoxanthine-guanine phosphoribosyl transferase activity – a tool for the treatment of hyperuricemia in gout, Expert Opin. Pharmacother. (2018) 1–11.
[20] R. Seth, A.S. Kydd, C. Bombardier, C.J. Edwards, Allopurinol for treatment of hyperuricemia in gout, Cochrane Database Syst. Rev. (10) (2014).
[21] R. Radi, H. Rubbo, K. Bush, B.A. Freeman, Xanthine oxidase binding to glycosa-minoglycans: kinetics and superoxide dismutase interactions of immobilized xan-thine oxidase-heparin complexes, Arch. Biochem. Biophys. 339 (1) (1997) 125–135.
[22] T. Adachi, T. Fukushima, Y. Usami, K. Hisano, Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface, Biochem. J. 289 (Pt 2) (1999) 523–527.
[23] M. Houston, et al., Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling, J. Biol. Chem. 274 (8) (1999) 4985–4994.
[24] P. Schaub, Cellular distribution, metabolism and regulation of the xanthine oxi-doreductase enzyme system, Chem. Biol. Interact. 129 (1 Pt 2) (2000) 195–208.
[25] W.B. Poss, T.P. Hückstedt, P.C. Panus, B.A. Freeman, J.R. Hoidal, Regulation of xanthine oxidase activity in the circulation of rats following hemorrhagic shock, Free Radic. Biol. Med. 15 (4) (1993) 407–414.
[26] C.R. White, et al., Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits, Proc. Natl. Acad. Sci. USA 93 (16) (1996) 8745–8749.
[27] U.Z. Malik, et al., Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production, Free Radic. Biol. Med. 51 (5) (2011) 179–184.
[28] R. Radi, H. Rubbo, K. Bush, B.A. Freeman, Xanthine oxidase binding to glycosa-minoglycans: kinetics and superoxide dismutase interactions of immobilized xan-thine oxidase-heparin complexes, Arch. Biochem. Biophys. 339 (1) (1997) 125–135.
[29] P. G. Thomas, et al., For the treatment of hyperuricemia in gout, Expert Opin. Pharmacother. (2018) 1–11.
[30] R. Seth, A.S. Kydd, R. Buchbinder, C. Bombardier, C.J. Edwards, Allopurinol for chronic gout, Cochrane Database Syst. Rev. (11) (2014).
[31] C. Keane, L. Stamp, A. Bahn, Molecular mechanism of an adverse drug-drug inter-action of allopurinol and furosemide in gout treatment, Biochem. Biophys. Res. Commun. 452 (1) (2014) 157–162.
[32] K. Okamoto, B.T. Eger, T. Nishino, S. Kondo, E.F. Pai, T. Nishino, An extremely potent inhibitor of xanthine oxidase, Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition, J. Biol. Chem. 278 (3) (2003) 1848–1855.
[33] K. Okamoto, T. Nishino, Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051, J. Nikon Med. Sch. 75 (1) (2008) 2–3.
[34] Y. Takano, et al., Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase, Life Sci. 76 (16) (2005) 1835–1847.
[35] C.T. Liu, et al., Risk of febuxostat-associated myopathy in patients with CKD, Clin. J. Am. Soc. Nephrol. 12 (5) (2017) 744–750.
[36] W.B. White, et al., Cardiovascular safety of febuxostat or allopurinol in patients with gout, N. Engl. J. Med. 378 (13) (2018) 1200–1210.
[51] U.R. Osarogiagbon, S. Choong, J.D. Belcher, G.M. Percellotti, M.S. Paller, R.P. Hebbel, Reperfusion injury pathophysiology in sickle transgenic mice, Blood 96 (1) (2000) 314–320.

[52] Y. Yokoyama, et al., Circulating xanthine oxidase: potential mediator of ischemic injury, Am. J. Physiol. 258 (4 Pt 1) (1990) G564–G570.

[53] P.M. Hassoun, et al., Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1, and hypoxia. Role in acute lung injury, Am. J. Respir. Crit. Care Med. 158 (1) (1998) 299–305.

[54] M.G. Battelli, et al., Serum xanthine oxidase in human liver disease, Am. J. Gastroenterol. 96 (4) (2001) 1194–1199.

[55] F. Stirpe, M. Ravaoli, M.G. Battelli, S. Musiani, G.L. Grazi, Xanthine oxidoreductase activity in human liver disease, Am. J. Gastroenterol. 97 (8) (2002) 2079–2085.

[56] S. Chatterjee, et al., Oxidative stress induces protein and DNA radical formation in follicular dendritic cells of the germinal center and modulates its cell death patterns in late sepsis, Free Radic. Biol. Med. 50 (8) (2011) 988–999.

[57] M.F.P. Ramos, A. Monteiro de Barros, C.V. Razvickas, F.T. Borges, N. Schor, Xanthine oxidase inhibitors and sepsis, Int. J. Immunopathol. Pharmacol. 32 (2018).

[58] N.H. Kim, et al., The xanthine oxidase-NFAT5 pathway regulates macrophage activation and TLR-induced inflammatory arthritis, Eur. J. Immunol. 44 (9) (2014) 2721–2736.

[59] P. Hahl, R. Hunt, E.S. Bjes, A. Skaff, A. Keightley, A. Smith, Identification of oxidative modifications of hemopexin and their predicted physiological relevance, J. Biol. Chem. 292 (33) (2017) 13658–13671.

[60] D.G. Silva, E. Belini Junior, E.A. de Almeida, C.R. Bonini-Domingos, Oxidative stress in sickle cell disease: an overview of erythrocyte redox metabolism and current antioxidant therapeutic strategies, Free Radic. Biol. Med. 65 (2013) 1101–1109.

[61] R. Henneberg, M.F. Otuki, A.E. Furman, P. Hermann, A.J. do Nascimento, M.S. Leonart, Protective effect of flavonoids against reactive oxygen species production in sickle cell anemia patients treated with hydroxyurea, Rev. Bras. Hematol. Hemoter. 35 (1) (2013) 52–55.